The role of periostin, eosinophil cationic protein (ECP), nesfatin-1, and NUCB2 in asthma and obesity.

Background: Obesity has a significant impact on asthma incidence and control. Nesfatin-1, encoded by the nucleobindin-2 (NUCB2) gene, regulates energy balance. This study aimed to evaluate NUCB2 gene polymorphism (rs757081 C > G) and its association with serum levels of nesfatin-1 and inflammatory cytokines in obese and non-obese patients with asthma.

Could Hepcidin Be a New Biomarker in Patients with Idiopathic Pulmonary Fibrosis (IPF)?

Hepcidin is a biomarker produced by hepatocytes in chronic disease anemia and is known to increase during chronic inflammation. This study compares the hepcidin levels in idiopathic pulmonary fibrosis (IPF) patients and controls, evaluating its relationship with anemia and systemic inflammation in IPF patients. This study included 82 IPF patients and 31 controls.

Could the HALP score serve as a biomarker of bronchiectasis exacerbation?

Introduction: Bronchiectasis is a chronic inflammatory lung disease and patients may occasionally experience acute exacerbations. Our study aims to determine the relationship between exacerbation periods and HALP (hemoglobin, albumin, lymphocyte, platelet) scores in patients with bronchiectasis.

Materials And Methods: Adult patients diagnosed with bronchiectasis and followed up in our clinic between 02.

Can the ADO Index Be Used as a Predictor of Mortality from COVID-19 in Patients with COPD?

Background: Several studies have shown that the risk of mortality due to COVID-19 is high in patients with COPD. However, evidence on factors predicting mortality is limited.

Research Question: Are there any useful markers to predict mortality in COVID-19 patients with COPD?.

Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?

Introduction: Long-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) have been recommended for symptom control in group A COPD patients as a first-line bronchodilator treatment in GOLD guidelines. However, there is no mention of priority/superiority between the two treatment options. We aimed to compare the effectiveness of these treatments in this group.